Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06178809
Status:
RECRUITING
Last Update Posted:
2024-01-03
First Post:
2023-12-11
Brief Title:
Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma
Sponsor:
Singlera Genomics Inc
Organization:
Singlera Genomics Inc
Study Overview
Official Title:
Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA Predicting Postoperative Recurrence and Progression After Systemic Therapy of Hepatocellular Carcinoma
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to combine biomarker characteristic atlas and ctDNA detection technology to establish a precise standard scheme for minimal residual diagnosis of liver cancer after surgery and systemic treatment
Detailed Description:
This study is a prospective single-blind randomized controlled single-center study The patients with liver cancer are recruited after surgery or systemic treatment Intraoperative cancer and para-cancer tissues of surgical patients are collected and peripheral blood of all patients after multiple follow-up visits before and after treatment are also collected The established detection method and model are used to detect blood ctDNA of patients with liver cancer after treatment and the follow-up data are collected to observe the correlation between the genomic characteristics of plasma at multiple follow-up points after treatment and the recurrence or progression after treatment The sensitivity and specificity of ctDNA detection method is calculated to predict the risk of relapse or progression after treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None